Biosig Technologies Inc logo

BSGM - Biosig Technologies Inc News Story

$4.57 0.1  2.0%

Last Trade - 09/04/21

Small Cap
Market Cap £106.0m
Enterprise Value £86.0m
Revenue £n/a
Position in Universe 4849th / 6827

BioSig Appoints Brenda Castrodad to Lead Human Resources

Tue 16th February, 2021 1:45pm
For best results when printing this announcement, please click on link below:

Westport, CT, Feb. 16, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc.
(NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology
company commercializing an innovative signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it appointed Ms. Brenda Castrodad to lead its
Human Resources department.

A seasoned executive, Ms. Castrodad brings a wealth of experience in leading
organizational development in start-ups and Fortune 500 companies within the
life sciences sector. Most recently, Ms. Castrodad led the HR department at
TissueTech, Inc., a Miami, FL-based biotech leader in regenerative amniotic
tissue-based products, where she was responsible for transformation and
automation of the company’s HR practices, talent planning, and team
building. Prior to TissueTech, Inc., Ms. Castrodad spent six years at
HeartWare, Inc., a heart failure medtech company acquired by Medtronic
 NYSE:MDT  in 2016 for $1.1 billion. By optimizing the internal talent
acquisition function and aligning business practices, Ms. Castrodad helped
grow the organization from approx. 80 to 500+ staff which achieved approx.
$250 million in revenues before the acquisition. Earlier in her career, Ms.
Castrodad spent 16 years at Schering-Plough Corp, a pharmaceutical company
acquired in 2009 for $41.1 billion by Merck & Co.  NYSE:MRK . Ms. Castrodad
holds a Master’s Degree in Public Administration and a Bachelor’s Degree
in Social Sciences – Human Welfare from the University of Puerto Rico and a
Labor Relations Certificate from the University of Michigan.

"A proven champion of culture, growth, and transformation, Brenda impressed us
with her experience in positioning HR as a strategic business partner to
create a platform for successful talent acquisition and employee engagement.
Brenda’s expertise in supporting rapid growth, combined with her knowledge
of our industry, should be invaluable as we scale up our customer-facing teams
while further developing the in-house talent to drive the innovation engine.
We look forward to working with Brenda as we prepare the Company for
commercial success,” commented Kenneth L. Londoner, Chairman, and CEO of
BioSig Technologies, Inc.

“It is a privilege to join the BioSig team of dedicated and experienced
professionals across the organization. I’m energized by the company’s
culture of innovation and commercialization plans.  I’m thrilled to be a
valuable contributor to the incredible growth path ahead of us,” commented
Brenda Castrodad.

About BioSig Technologies
 BioSig Technologies is a medical technology company commercializing a
proprietary biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (

The Company’s first product, PURE EPä System is a computerized system
intended for acquiring, digitizing, amplifying, filtering, measuring and
calculating, displaying, recording and storing of electrocardiographic and
intracardiac signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements
may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or
similar words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to various known
and unknown risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without
limitation, risks and uncertainties associated with (i) the geographic, social
and economic impact of COVID-19 on our ability to conduct our business and
raise capital in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own, or in
collaboration with third parties; (iii) difficulties in obtaining financing on
commercially reasonable terms; (iv) changes in the size and nature of our
competition; (v) loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products and
product candidates. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking statements is set
forth in the Company’s filings with the Securities and Exchange Commission
(SEC), including the Company’s Annual Report on Form 10-K and its Quarterly
Reports on Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at The
Company assumes no obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or otherwise.

Andrew Ballou
BioSig Technologies, Inc. 
Vice President, Investor Relations 
54 Wilton Road, 2nd floor
Westport, CT 06880
203-409-5444, x133


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.